Comparison of Miltefosine and Meglumine Antimoniate in Treatment of Leishmaniasis; a review of literature

سال انتشار: 1398
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 370

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

DCME02_143

تاریخ نمایه سازی: 19 آذر 1398

چکیده مقاله:

Background: Leishmaniasis is one of the most challenging infections to be controlled which is growing as a life-threatening illness in the last two decades. It is caused by Leishmania, a protozoan parasite. Due to some studies in the past years, almost half of the leishmaniasis cases do not respond to the administration of meglumine antimoniate (MA). Some studies have shown miltefosine s well tolerance and its effective respond against Leishmaniasis.Objectives: The aim of this study is to evaluate the safety and efficacy of miltefosine compared to MA in the treatment of leishmaniasis.Materials and Methods: A literature search was performed in WEB of SCIENCE, MEDLINE and PUBMED databases using the keywords leishmaniasis , miltefosine and meglumine antimoniate in order to compare the effects of miltefosine and MA for the treatment of leishmaniasis. No restrictions were considered. The references in relevant reviews and published clinical trials were included in the study.Results: The results of the studies showed that the cure rate of miltefosine was a little bit higher and better than the cure rate in the MA group. In the miltefosine group, there was no failure but there were five failed ones in the MA group. In one study failure rate for miltefosine was considerably lower than the MA and the total difference between them was considerable. In another study therapeutic failure was 15.65% which was also lower for miltefosine. In two studies, they observed no differences in cure probability. Averages of side effects such as nausea and vomiting were higher in miltefosine group but other total adverse effects were not statistically different in the two groups in controversy to another study which showed gastrointestinal effects were more frequent in the miltefosine group. There were no changes in levels of liver enzymes, creatinine and hematological tests for both.Conclusion: Miltefosine decreased cost-per-cure for society and patients and it is at least as good as meglumine but contradictory information indicates the need for more future studies

نویسندگان

m Malekian

Midwifery student, Tehran University of Medical Sciences, Iran, Tehran

m Irani

Nursing student, Tehran University of Medical Sciences, Iran, Tehran